Beike has published ground-breaking research in the adult stem cell field for over 10 years, utilizing umbilical cord blood and tissue as a source of stem cells.
Beike provides and researches stem cells from two sources: umbilical cord blood and umbilical cord tissue. For some treatments, the research protocols may include the use of more than one type of stem cell.
For many conditions, such as spinal muscular atrophy, ataxia, and optic nerve conditions, Beike has developed novel treatments using umbilical cord blood (UCB) stem cells. Our UCB stem cell injections consist of three subsets of stem cells: hematopoietic stem cells, endothelial progenitor cells, and mesenchymal stem cells. Hematopoietic stem cells and endothelial progenitor stem cells have been shown to develop into functional tissues. Mesenchymal stem cells can assist in the growth of chondrocytes – a type of cell critical to tissue renewal, particularly cartilage – as well as liver cells, kidney cells and neurons. In addition, such cells also possess the ability to aid in the repair of a variety of vascular disorders within the brain, eye, and throughout the body including the heart, kidney, and pancreas. From our findings to date, it is believed that the benefits patients report following treatment arise from the cell growth factors that are released by stem cells following administration.
Based upon recent research and experience, Beike protocols utilize UCMSC for the treatment of conditions amenable to stem cell therapy. Our injections contain a higher percentage of mesenchymal stem cells than UCB stem cell injections and closely resemble the composition of cells cultured from bone marrow. As per our currently clinical guidelines, we recommend multiple sclerosis (MS) and spinal cord injury (SCI) patients receive this type of stem cell injection. Previously published studies have demonstrated UCMSC produce important chemicals, known as growth factors, and have the ability to differentiate into desired cell types, as well possessing the property of modulating the immune system, reducing inflammation, scarring, and reducing cellular apoptosis.
Below you can see Beike’s published research papers, as well as clinical translation case studies for stem cell treatments of a plethora of medical conditions. The papers are listed alphabetically.
MAR (Major Histocompatibility Antigen Receptor) is a class of fully human single domain antibodies that bind MHC antigen complex and is a “T-cell receptor (TCR)-like antibody”. Binding to MHC antigen complexes enables MAR to be directed against intracellular targets, opening up novel possibilities to cancer immunotherapies.
For more information on MAR please visit http://timmune.com, our subsidiary for these technologies.
TriTE (Tri-functional T cell Engager) is a fusion protein platform with a unique combination of antigen binding domains, a Sushi domain IL-15 binding pair and PD1. It provides an improved microenvironment for cancer immunotherapy.
For more information on TriTE please visit http://timmune.com, our subsidiary for these technologies.
MAR-T is a variant of CAR-T for adoptive T cell cancer therapy. It utilizes part of our proprietary TriTE platform and MAR and results in T cells with improved micro-environment functions and a higher number of binding targets with better binding specificity and affinity. This increases its potential for cancer immunotherapies over the traditional CAR-T.
For more information on MAR-T please visit http://timmune.com, our subsidiary for these technologies.